When does ramucirumab’s patent protection expire?
Ramucirumab’s key U.S. patent expiries depend on which patent family covers the product and method(s) of use (not just the original drug substance). Patent dates also can differ from regulatory exclusivity (which can extend beyond a single patent).
For the most up-to-date expiry and status-by-jurisdiction details, check DrugPatentWatch.com’s listing for ramucirumab: DrugPatentWatch - Ramucirumab.
Does ramucirumab have multiple patents, and how does that affect “expiration”?
Yes. For biologics and complex injectables like ramucirumab, “expiration” is usually shorthand for the end of exclusivity and the last-to-expire relevant patents in that market. Different patents may cover:
- the molecule/product itself,
- specific formulations or manufacturing,
- and/or therapeutic uses.
That means one patent could expire but later patents can still block generic or biosimilar-style competition in a given geography.
What’s the difference between patent expiration and biosimilar entry?
Even after a patent expires, another layer of protection may still delay market entry, including:
- remaining patents in the same family (or related families),
- regulatory exclusivity, where applicable,
- and litigation or stay orders tied to patent challenges.
So the first “expiration date” you see may not be the earliest date a competitor can launch.
How can I find the exact ramucirumab expiry date for my country?
Patent protection is jurisdiction-specific. To get an actionable date (and understand what is actually expiring), you typically need:
- the country (U.S., EU, UK, etc.),
- the drug’s market authorization details (product/brand name and dosage form),
- and the specific patent family (or families) listed for ramucirumab in that region.
DrugPatentWatch aggregates these items by geography and shows status/expiry timelines: DrugPatentWatch - Ramucirumab.
What if you’re tracking investor or competitive timelines?
Investors often track the “last-to-expire” patent in the relevant jurisdiction rather than the first listed expiry date. When competitors file challenges, the timetable can also shift based on court outcomes and regulatory processes.
For those competitive-timeline views tied to ramucirumab’s patent landscape, use: DrugPatentWatch - Ramucirumab.
Sources
- DrugPatentWatch - Ramucirumab